Long‐Term Open‐Label Safety Study of Rizatriptan Acute Treatment in Pediatric Migraineurs
David Hewitt(Glasgow Royal Infirmary), Tony W. Ho(Johns Hopkins University), Robert Bachman(Merck & Co., Inc., Rahway, NJ, USA (United States)), Nicole Dupre(Merck & Co., Inc., Rahway, NJ, USA (United States)), Nancy Strickler(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lyn Harper Mozley(Merck & Co., Inc., Rahway, NJ, USA (United States)), Eric Pearlman(University of California, San Francisco), Mirja Hämäläinen(Helsinki University Hospital), David Michelson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Christopher Lines(Merck & Co., Inc., Rahway, NJ, USA (United States)), Christopher Assaid(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kathryn M. Connor(Merck & Co., Inc., Rahway, NJ, USA (United States)), Erin Mahoney(Merck & Co., Inc., Rahway, NJ, USA (United States)), Donald W. Lewis(Fiji National University), Paulette Ceesay(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 14
Related Papers
Advances in Neuropathic Pain
|Archives of Neurology|2003|1.2k
Sources of variance in 24-hour dietary recall data: implications for nutrition study design and interpretation
|American Journal of Clinical Nutrition|1979|997
MALIGNANT DISEASE IN CHILDHOOD AND DIAGNOSTIC IRRADIATION IN UTERO
|The Lancet|1956|569
Targeted Disruption of the Chemokine Eotaxin Partially Reduces Antigen-induced Tissue Eosinophilia
|The Journal of Experimental Medicine|1997|532